Table 3.
Clinicopathological characteristics and univariate analysis of 122 cases of PTMC patients who underwent prophylactic CLND
| Characteristics | Total (n = 122) | CLNM + (n = 60) | CLNM - (n = 62) | P Value |
|---|---|---|---|---|
| Gender (M/F) |
60/62 |
44/16 |
16/46 |
0.015a |
|
Age ± SD (years) |
48 ± 11 |
46 ± 10 |
50 ± 11 |
0.044a,b |
| ≥45/<45 |
83/39 |
37/23 |
46/16 |
0.138 |
| ≥50/<50 |
57/65 |
21/39 |
36/26 |
0.011a |
|
Tumor size ± SD (mm) |
6.5 ± 2.6 |
7.2 ± 2.3 |
5.8 ± 2.7 |
0.002a,b |
| ≥5/<5 |
95/27 |
51/9 |
44/18 |
0.062 |
| ≥7/<7 |
59/63 |
36/24 |
23/39 |
0.011a |
| Multifocality (%) |
19 (15.6) |
14 (23.3) |
5 (8.1) |
0.020a |
| ETE (%) |
7 (5.7) |
5 (8.3) |
2 (3.2) |
0.269c |
| T stage (T1/2:T3/4) |
115/7 |
55/5 |
60/2 |
0.269c |
| With HT (%) |
43 (35.2) |
19 (31.7) |
24 (38.7) |
0.416 |
| Bilateral PTMC (%) |
60 (50.8) |
26 (61.9) |
34 (42.5) |
0.042a |
|
Preoperative tumor size (mm) |
6.8 ± 2.8 |
7.5 ± 2.6 |
6.1 ± 2.9 |
0.008a |
| ≥5/<5 |
99/23 |
52/8 |
47/15 |
0.125 |
| ≥7/<7 |
61/61 |
37/23 |
24/38 |
0.001a |
| Preoperative multifocality (%) | 16(13.1) | 12(20.0) | 4(6.6) | 0.027a |
a Statistically significant (P < 0.05).
bCalculated using two-tailed student t test.
cCalculated using Fisher exact test, others calculated using chi-square test.
CLNM, central lymph node metastasis; ETE, extrathyroidal extension; HT, Hashimoto thyroiditis; PTMC, papillary thyroid microcarcinoma.